Article Figures & Data
Tables
Characteristic Sex, male/female 57:129 (1:2.3) Age (yr) 58.3 ± 10.2 Body weight (Kg) 63.6 ± 10.7 Hypertension 94 (51%) Diabetes mellitus 15 (8%) Statin use 31 (17%) Smoking Smoker 36 (19%) Nonsmoker 150 (81%) Alcohol intake 36 (19%) Hematocrit level (%) 38.2 ± 4.3 Platelet count (×103/μL) 227 ± 60 Total cholesterol level (mg/dL) 181.1 ± 36.8 Triglyceride level (mg/dL) 150.3 ± 85.6 HDL cholesterol level (mg/dL) 51.1 ± 17.5 LDL cholesterol level (mg/dL) 109.0 ± 32.5 Mode of medication CPG loading (300 mg) only 136 (73%) Previous other antiplatelet medication plus CPG loading 29 (16%) Continued CPG medication without loading 21 (11%) -
a All the continuous variables are presented as mean ± SD.
-
Quartile (No.) PRU Thromboembolic Events Procedure-Related Aneurysmal Perforations All Procedure-Related Adverse Events 1st (47) <240 2 (4.3%) 1 (2.1%) 3 (6.4%) 2nd (46) 240–284 1 (2.2%) 0 (0%) 1 (2.2%) 3rd (46) 285–332 3 (6.5%) 0 (0%) 3 (6.5%) 4th (47) >332 8 (17.0%) 2 (4.3%) 10 (21.3%) P valuea .013 .605 .009 -
a χ2 test for trends.
-
Clinical and Laboratory Variables P PRU Sex (male) <.001 244 ± 68 vs 291 ± 78 Age (younger than 65 years) .028 268 ± 80 vs 295 ± 72 Body weight (≥60 Kg) .031 267 ± 78 vs 292 ± 76 CPG medication (≥7 days) .003 230 ± 96 vs 283 ± 74 Combination antiplatelet medication (yes) .175 263 ± 83 vs 281 ± 76 Hypertension (no) .745 275 ± 78 vs 278 ± 78 Diabetes mellitus (yes) .184 251 ± 99 vs 279 ± 76 Statin use (no) .198 274 ± 78 vs 293 ± 77 Smoking status (current or past smoker) .071 256 ± 73 vs 282 ± 79 Alcohol intake (yes) .157 260 ± 76 vs 280 ± 78 Hematocrit level (≥38%) .008 263 ± 73 vs 293 ± 81 Platelet count (<227 × 103/μL) .562 274 ± 80 vs 280 ± 76 Total cholesterol level (<200 mg/dL) .232 273 ± 80 vs 288 ± 71 HDL cholesterol level (≥40 mg/dL) .225 275 ± 79 vs 292 ± 69 LDL cholesterol level (≥130 mg/dL) .608 273 ± 75 vs 280 ± 78 Triglyceride level (<200 mg/dL) .091 274 ± 77 vs 299 ± 72 Procedure-related thromboembolism (no) .061 274 ± 78 vs 318 ± 54 -
a A group of patients denoted within the parentheses showed decreased residual platelet activity.
-
Mode of Administration BASE PRU Percentage Inhibition CPG loading (300 mg) only, 136 (73%) 360.8 ± 51.8 285.2 ± 71.6 20.6 ± 18.4 Previous other antiplatelet medication plus CPG loading (300 mg), 29 (16%) 358.8 ± 63.0 271.7 ± 82.9 24.5 ± 19.2 Continued CPG medication for ≥7 days without loading, 21 (11%) 371.9 ± 45.1 230.0 ± 96.2 37.4 ± 26.3 P valuea .6388 .0091b .0013b -
a One-way ANOVA.
-
b There was a significant difference between the first group and the third group on the Tukey-Kramer multiple comparison test (P < .01).
-
Variables P Value Simple Logistic Regression Analysis Multiple Logistic Regression Analysisa Gender .001 .014 Age .241 Body weight .009 .547 Mode of CPG medication .096 .086 Combination therapy .255 Hypertension .800 Diabetes mellitus .626 Statin use .598 Smoking .088 .114 Alcohol intake .373 Hematocrit level .049 .169 Platelet count .058 .141 Total cholesterol level .443 Triglyceride level .159 HDL cholesterol level .287 LDL cholesterol level .499 -
a Variables with P < 0.10 were entered into multivariate analysis to determine their independent association with high PRU.
-
In this issue
Jump to section
Related Articles
Cited By...
- Roles of light transmission aggregometry and CYP2C19 genotype in predicting ischaemic complications during interventional therapy for intracranial aneurysms
- The inhibition rate estimated using VerifyNow can help to predict the thromboembolic risk of coil embolization for unruptured intracranial aneurysms
- Ticagrelor resistance: a case series and algorithm for management of non-responders
- Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives
- Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention
- Selective compromise of hypoplastic posterior communicating artery variants with aneurysms treatable by coil embolization: clinical and radiologic outcomes
- Stent-assisted coil embolization of anterior communicating artery aneurysms: safety, effectiveness, and risk factors for procedural complications or recanalization
- Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis
- Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel
- Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms
- Association between Postprocedural Infarction and Antiplatelet Drug Resistance after Coiling for Unruptured Intracranial Aneurysms
- Endovascular Treatment of Unruptured Paraclinoid Aneurysms: Single-Center Experience with 400 Cases and Literature Review
- Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate
- Incidence and Risk Factors for Diffusion-Weighted Imaging (+) Lesions After Intracranial Stenting and Its Relationship With Symptomatic Ischemic Complications
- Thromboembolic Complications in Patients with Clopidogrel Resistance after Coil Embolization for Unruptured Intracranial Aneurysms
- Stent-Assisted Coil Embolization of Posterior Communicating Artery Aneurysms
- Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices
- Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices
- Endovascular Treatment of Wide-Neck Intracranial Aneurysms Using a Microcatheter Protective Technique: Results and Outcomes in 75 Aneurysms